Chiara R.
- Country
- Italy
- Department
- Gastroenterologia
Research Overview
- Long-Term Safety and Efficacy Evaluation of Oral Ozanimod in Patients with Moderately to Severely Active Crohn's Disease: A Phase 3 Multicenter Study
- Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Trial of Oral Ozanimod for Maintenance in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety Evaluation of RO7790121 Induction Therapy in Moderately to Severely Active Ulcerative Colitis: A Phase III Multicenter Double-Blind Placebo-Controlled Study
Data & Insights
Has run more than one trial at 145 of 213 partner sites.
Specializations
Inflammatory Bowel Disease Research
The investigator specializes in the treatment of moderately to severely active Crohn's Disease, focusing on innovative therapeutic approaches for managing this chronic inflammatory condition.
- Novel therapeutic agents evaluation
- Clinical remission assessment
- Endoscopic response monitoring
Their research encompasses both induction and maintenance therapy strategies for inflammatory bowel conditions.
Treatment Innovation
The investigator conducts research on targeted immunomodulatory therapies, including studies with novel compounds like RO7790121 and ozanimod for gastrointestinal disorders.
- Oral medication development
- Long-term therapeutic outcomes
- Safety profile evaluation
Their work focuses on developing effective treatment options for patients with inflammatory bowel conditions.
Clinical Outcomes
The investigator evaluates therapeutic efficacy markers in gastrointestinal medicine, with particular attention to clinical and endoscopic endpoints.
- Disease activity assessment
- Treatment response monitoring
- Long-term disease management
Their research emphasizes comprehensive evaluation of treatment effectiveness in inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.